Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01460407 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Effect of Clarithromycin on LY2216684
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT01460407 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 14 participants.
The verdict
NCT01460407, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
The study will evaluate the effect of Clarithromycin on the pharmacokinetics (PK) of LY2216684 in healthy participants. Side effects will be documented. There will be 2 study periods (5 and 9 days) and follow up will occur at least 7 days after the last dose. Screening is required within 45 days prior to the start of the study.
Interventions
- DRUG Clarithromycin
- DRUG LY2216684
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2011-10 |
| Est. Completion | 2011-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01460407
The ClinicalTrials.gov registry entry for NCT01460407 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Clarithromycin is the first listed.
NCT01460407 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01460407 about?
NCT01460407 is a clinical study titled "A Study to Evaluate the Effect of Clarithromycin on LY2216684". The study will evaluate the effect of Clarithromycin on the pharmacokinetics (PK) of LY2216684 in healthy participants. Side effects will be documented. There will be 2 study periods (5 and 9 days) and follow up will occur at least 7 days after the last dose. Screening is required within 45 days pri...
What is the current status of trial NCT01460407?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2011-10. Estimated completion is 2011-12.
What interventions are being tested in trial NCT01460407?
The interventions under investigation include: Clarithromycin (DRUG), LY2216684 (DRUG).
Who is sponsoring clinical trial NCT01460407?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.